[go: up one dir, main page]

BRPI0810396A2 - Nanopartícula que compreende um polímero biodegradável, uma ciclodextrina ou um derivado desta, composição farmacêutica e processo para produzir nanopartículas - Google Patents

Nanopartícula que compreende um polímero biodegradável, uma ciclodextrina ou um derivado desta, composição farmacêutica e processo para produzir nanopartículas

Info

Publication number
BRPI0810396A2
BRPI0810396A2 BRPI0810396-8A2A BRPI0810396A BRPI0810396A2 BR PI0810396 A2 BRPI0810396 A2 BR PI0810396A2 BR PI0810396 A BRPI0810396 A BR PI0810396A BR PI0810396 A2 BRPI0810396 A2 BR PI0810396A2
Authority
BR
Brazil
Prior art keywords
cyclodextrin
nanoparticle
derivative
pharmaceutical composition
biodegradable polymer
Prior art date
Application number
BRPI0810396-8A2A
Other languages
English (en)
Inventor
Maite Agueeros Bazo
Hesham H A Salman
Juan Manuel Irache Garreta
Miguel Angel Campanero Martinez
Original Assignee
Inst Cientifico Tecnol Navarra
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inst Cientifico Tecnol Navarra filed Critical Inst Cientifico Tecnol Navarra
Publication of BRPI0810396A2 publication Critical patent/BRPI0810396A2/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51Nanocapsules; Nanoparticles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0065Forms with gastric retention, e.g. floating on gastric juice, adhering to gastric mucosa, expanding to prevent passage through the pylorus
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51Nanocapsules; Nanoparticles
    • A61K9/5107Excipients; Inactive ingredients
    • A61K9/513Organic macromolecular compounds; Dendrimers
    • A61K9/5138Organic macromolecular compounds; Dendrimers obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51Nanocapsules; Nanoparticles
    • A61K9/5107Excipients; Inactive ingredients
    • A61K9/513Organic macromolecular compounds; Dendrimers
    • A61K9/5161Polysaccharides, e.g. alginate, chitosan, cellulose derivatives; Cyclodextrin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B82NANOTECHNOLOGY
    • B82YSPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Nanotechnology (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Medical Informatics (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
BRPI0810396-8A2A 2007-04-20 2008-04-18 Nanopartícula que compreende um polímero biodegradável, uma ciclodextrina ou um derivado desta, composição farmacêutica e processo para produzir nanopartículas BRPI0810396A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ES200701074A ES2310122B1 (es) 2007-04-20 2007-04-20 Nanoparticulas que comprenden una ciclodextrina y una molecula biologicamente activa y sus aplicaciones.
PCT/ES2008/000269 WO2008129106A2 (es) 2007-04-20 2008-04-18 Nanopartículas que comprenden una ciclodextrina y una molécula biológicamente activa y sus aplicaciones

Publications (1)

Publication Number Publication Date
BRPI0810396A2 true BRPI0810396A2 (pt) 2014-11-04

Family

ID=39643881

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0810396-8A2A BRPI0810396A2 (pt) 2007-04-20 2008-04-18 Nanopartícula que compreende um polímero biodegradável, uma ciclodextrina ou um derivado desta, composição farmacêutica e processo para produzir nanopartículas

Country Status (11)

Country Link
US (1) US9522197B2 (pt)
EP (1) EP2153826B1 (pt)
JP (1) JP5847397B2 (pt)
CN (1) CN101686949A (pt)
AU (1) AU2008240545B2 (pt)
BR (1) BRPI0810396A2 (pt)
CA (1) CA2684560C (pt)
ES (2) ES2310122B1 (pt)
MX (1) MX2009011247A (pt)
RU (1) RU2460518C2 (pt)
WO (1) WO2008129106A2 (pt)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8372877B2 (en) * 2010-04-16 2013-02-12 Cumberland Pharmaceuticals Stabilized statin formulations
AU2014277744B2 (en) * 2010-04-16 2017-01-19 Cumberland Pharmaceuticals, Inc. Stabilized Statin Formulations
EA016410B1 (ru) * 2010-11-13 2012-04-30 Ооо "Нпк Наносистема" Фармацевтическая композиция на основе наночастиц циклодекстрина, содержащих рифабутин, способ ее получения, способ лечения микобактериоза и геликобактерной инфекции (варианты)
US20140017330A1 (en) * 2011-04-04 2014-01-16 Board Of Regents Of The University Of Nebraska Activated Nucleoside Analog Conjugates and Methods of Use Thereof
EP2510930A1 (en) 2011-04-15 2012-10-17 Bionanoplus, S.L. Nanoparticles comprising half esters of poly (methyl vinyl ether-co-maleic anhydride) and uses thereof
JP5391229B2 (ja) * 2011-04-27 2014-01-15 富士フイルム株式会社 木構造抽出装置および方法ならびにプログラム
CN102670513B (zh) * 2012-02-22 2014-03-19 河南碧云天动物药业有限公司 氧氟沙星分子包合纳米制剂及其制备方法
CN104244986B (zh) * 2012-03-13 2016-11-16 浦项工科大学校产学协力团 可控释的药物递送缀合物及其应用
CN102579402B (zh) * 2012-03-26 2013-07-03 山东大学 一种负载紫杉醇的囊泡的制备方法
US8916697B2 (en) * 2012-03-30 2014-12-23 Purdue Research Foundation Nucleic acid complexes
EP2919801B1 (en) * 2012-10-26 2020-04-29 Lupin Atlantis Holdings, SA Stable pharmaceutical composition of the tnfr:fc fusion protein etanercept
FR3000080B1 (fr) * 2012-12-20 2015-01-30 Oreal Polycondensat de cyclodextrine insoluble dans l'eau ; utilisations comme agent de capture
CN103142499B (zh) * 2013-03-21 2014-10-01 青岛正大海尔制药有限公司 一种依托泊苷颗粒
CN103705987B (zh) * 2014-01-02 2015-10-07 东南大学 一种具有ct造影功能的葡聚糖栓塞微球的制备方法
RU2546535C1 (ru) * 2014-04-09 2015-04-10 Федеральное государственное бюджетное учреждение науки Институт химии твердого тела и механохимии Сибирского отделения Российской академии наук (ИХТТМ СО РАН) Противопаразитарное средство на основе альбендазола и способ его использования для лечения гельминтозов млекопитающих
KR20170023173A (ko) * 2014-07-03 2017-03-02 화이자 인코포레이티드 표적화된 치료 나노입자 및 그의 제조 및 사용 방법
CN104387592B (zh) * 2014-11-29 2017-09-26 沈阳药科大学 环糊精‑甲基乙烯基醚/马来酸酐共聚物及其自组装纳米粒在口服药物传递中应用
WO2016087340A1 (en) 2014-12-01 2016-06-09 Innoup Farma, S.L. Nanoparticles for encapsulating compounds, the preparation and uses thereof
CN105194687A (zh) * 2015-10-22 2015-12-30 浙江医药高等专科学校 沙喹那韦或其甲磺酸盐的环糊精包合物制备方法
CN105561406A (zh) * 2016-02-15 2016-05-11 丹阳纳瑞康纳米科技有限公司 一种含复合药物涂层的血管支架
CN105695148B (zh) * 2016-02-24 2018-11-02 江阴市佐恩精品衣物洗涤护理有限公司 一种环保型固体清洗剂组合物
US10611823B2 (en) 2016-12-14 2020-04-07 Hanssen Biotech, Inc CD137 binding fibronectin type III domains
EP3554562A4 (en) 2016-12-14 2020-11-04 Janssen Biotech, Inc. DOMAINS OF TYPE III FIBRONECTIN BINDING TO CD8A
US10800817B2 (en) 2016-12-19 2020-10-13 Morehouse School Of Medicine Compositions and methods for treating diseases by inhibiting exosome release
US12064517B1 (en) 2018-12-03 2024-08-20 Hui Xie Polymer nanoparticle
CN109602724B (zh) * 2019-02-21 2022-02-11 江苏省中医药研究院 一种牛蒡子苷元口服纳米制剂及其制备方法
WO2021076574A2 (en) 2019-10-14 2021-04-22 Aro Biotherapeutics Company Fn3 domain-sirna conjugates and uses thereof
WO2021076543A1 (en) 2019-10-14 2021-04-22 Aro Biotherapeutics Company Epcam binding fibronectin type iii domains
CN119119240A (zh) 2019-10-14 2024-12-13 Aro生物疗法公司 结合cd71的纤维粘连蛋白iii型结构域
CN110898015A (zh) * 2019-12-31 2020-03-24 上海汉维生物医药科技有限公司 一种伊曲康唑制剂的制备方法
AU2022258584A1 (en) 2021-04-14 2023-10-12 Aro Biotherapeutics Company Fn3 domain-sirna conjugates and uses thereof
BR112023021325A2 (pt) 2021-04-14 2023-12-19 Aro Biotherapeutics Company Domínios de fibronectina tipo iii de ligação a cd71
CN113777100B (zh) * 2021-08-27 2022-11-01 厦门大学 一种基于主客体作用的定量物质控释系统及方法
CN114053229B (zh) * 2022-01-17 2022-04-22 山东国邦药业有限公司 一种盐酸沙拉沙星水溶性颗粒剂及其制备方法
CN118490645B (zh) * 2024-07-17 2024-09-20 中国农业科学院农业环境与可持续发展研究所 一种氟苯尼考纳米粉及其制备方法和应用
CN119700682B (zh) * 2024-12-16 2025-10-31 山东大学 一种聚环糊精/二甲氧乙二酰甘氨酸复合纳米颗粒及其制备方法与应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU213200B (en) * 1993-05-12 1997-03-28 Chinoin Gyogyszer Es Vegyeszet The cyclodextrin or cyclodextrin derivative cluster complexes of taxol, taxotere, or taxus, pharmaceutical preparations containing them and process for their production
US6515016B2 (en) * 1996-12-02 2003-02-04 Angiotech Pharmaceuticals, Inc. Composition and methods of paclitaxel for treating psoriasis
FR2775435B1 (fr) * 1998-02-27 2000-05-26 Bioalliance Pharma Nanoparticules comprenant au moins un polymere et au moins un compose apte a complexer un ou plusieurs principes actifs
WO2002041829A2 (en) 2000-11-20 2002-05-30 Pr Pharmaceuticals, Inc. Oral nanosphere delivery
ES2178961B1 (es) 2001-03-06 2004-07-01 Instituto Cientifico Y Tecnologico De Navarra, S.A. Fabricacion de nanoparticulas a base del copolimero de metil vinil eter y anhidrido maleico para la administracion de farmacos de naturaleza hidrofilica, en particular de bases puricas y pirimidinicas.
FR2830017B1 (fr) * 2001-09-27 2005-11-04 Centre Nat Rech Scient Materiau compose d'au moins un polymere biodegradable et de cyclodextrines
GB0127677D0 (en) * 2001-11-19 2002-01-09 Vianex S A Inclusion complex
ES2246694B1 (es) * 2004-04-29 2007-05-01 Instituto Cientifico Y Tecnologico De Navarra, S.A. Nanoparticulas pegiladas.
ES2277743B2 (es) 2005-06-02 2008-12-16 Universidade De Santiago De Compostela Nanoparticulas que comprenden quitosano y ciclodextrina.

Also Published As

Publication number Publication date
JP2010524902A (ja) 2010-07-22
ES2310122A1 (es) 2008-12-16
WO2008129106A2 (es) 2008-10-30
CA2684560C (en) 2016-06-14
WO2008129106A3 (es) 2009-03-05
MX2009011247A (es) 2010-01-29
RU2460518C2 (ru) 2012-09-10
EP2153826B1 (en) 2018-06-27
AU2008240545B2 (en) 2013-06-06
CN101686949A (zh) 2010-03-31
JP5847397B2 (ja) 2016-01-20
EP2153826A2 (en) 2010-02-17
RU2009142806A (ru) 2011-05-27
ES2684554T3 (es) 2018-10-03
US9522197B2 (en) 2016-12-20
US20100136129A1 (en) 2010-06-03
AU2008240545A1 (en) 2008-10-30
CA2684560A1 (en) 2008-10-30
ES2310122B1 (es) 2009-10-30

Similar Documents

Publication Publication Date Title
BRPI0810396A2 (pt) Nanopartícula que compreende um polímero biodegradável, uma ciclodextrina ou um derivado desta, composição farmacêutica e processo para produzir nanopartículas
BRPI0716663A2 (pt) Processo para produzir um produto de nanopartículas de biopolímero
BRPI0918389A2 (pt) partícula de resina absorvente, absorvente, artigo absorvente e processo para produção de partícula de resina absorvente
BRPI0923216A2 (pt) composição de resina, artigo moldado, e, processo para produzir uma composição de resina.
BRPI0905080A2 (pt) Composições, processo para reparar uma composição e produto
BRPI0813611A2 (pt) "composição, polímero, processo para preparar um polímero e artigo"
BRPI0816523A2 (pt) composição polimérica e processo para fabricar um artigo moldado
BRPI0920955A2 (pt) processo para a preparação de uma composição polimérica , composição polimérica, misturas, e, uso da composição polimérica
BR112012006333A2 (pt) método para produzir um polímero à base de dieno conjugado modificado, polímero à base de dieno conjugado modificado, e, composição do mesmo.
BRPI0905847A2 (pt) "composição farmacêutica injetável e processo para preparar a composição"
BR112012015100A2 (pt) composição de polímero modificado, artigo e método para produzir uma composição de polímero modificado
BRPI0919776A2 (pt) sistema , composição de resina, método para fabricar um objeto tridimensional, e, artigo curado
BRPI0907162A2 (pt) Composto, composição farmacêutica e métodos para ativar procaspase executora 3, 6 e/ou 7 e para tratar um estado de doença em um mamífero
BRPI0720068A2 (pt) Processo para preparar nanocápsulas, produto, nanocápsulas e composição
BRPI0812064A2 (pt) Formulação farmacêutica, tabletes, e, processo para a produção de uma formulação farmacêutica
BR112012007289A2 (pt) composição de resina de poléster, fibra de poliéster, artigo moldado de resina de poliéster e processo para a produção do agente de nucleação para resina de poliéster
BRPI0914646A2 (pt) 'processo e sistema para produzir singas e produtos de hidrocarbonetos
BRPI0812621A2 (pt) Processo para produzir uma dispersão contendo partículas de celulose ligeiramente oxidada, dispersão contendo partículas de celulose ligeiramente oxidada e partículas de celulose ligeiramente oxidada
EP2130842A4 (en) METHOD FOR MANUFACTURING MODIFIED CONJUGATED DIENE POLYMER, MODIFIED CONJUGATED DIENE POLYMER, AND RUBBER COMPOSITION
BRPI0920515A2 (pt) Métodos para produzir nanopartículas de polímero e formulações de ingredientes ativos
BRPI0906804A2 (pt) Método para liofilizar partículas, e, acondicionamento farmacêutico
BRPI0810650A2 (pt) " método e dispositivo para fechar a extremidade final de uma tora de material de manta e tora obtida ".
BR112012004216A2 (pt) "estereocomplexo de ácido poliláctico, método para produzir um estereocomplexo de ácido poliláctico, agente nucleante para resina de ácido poliláctico, método para produzir um composição de resina de ácido poliláctico e produto moldado"
BRPI0923859A2 (pt) Nanopartícula, composição, métodos para a produção das nanopartículas e de uso, e, uso de nanopartículas.
BRPI0916936A2 (pt) composições faramacêuticas e métodos para produzir baixas concentrações de impureza da mesmas.

Legal Events

Date Code Title Description
B25A Requested transfer of rights approved

Owner name: UNIVERSIDAD DE NAVARRA (ES)

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B15K Others concerning applications: alteration of classification

Ipc: A61K 9/00 (2006.01), A61K 9/51 (2006.01), A61K 31/

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B12B Appeal against refusal [chapter 12.2 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]